{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-013568","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.211669+00:00","generated_at":"2026-06-06T04:13:45.710018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026","bullets":["Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.","R&D expenses decreased 44% YoY to $1.4M due to resource prioritization on GTX-104.","Cash, equivalents and ST investments $25.1M; runway extended into 2nd calendar Q 2026.","Pivotal STRIVE-ON Phase 3 trial enrollment ongoing; NDA submission on track for 1H 2025.","Company secured $7.5M private placement in prior quarter to bolster balance sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-013568","json":"https://secwatch.observer/filing/0000950170-24-013568.json","markdown":"https://secwatch.observer/filing/0000950170-24-013568.md","text":"https://secwatch.observer/filing/0000950170-24-013568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/0000950170-24-013568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/acst-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:13:45.710018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"303353b8b33e499562448bf4c285be9cb2341118","claim":"Grace Therapeutics, Inc. reported the quarter ended December 31, 2023 results: net income $2.4 million, EPS $0.21 per share.","evidence_excerpt":"The Company reported a net loss of $2.4 million, or $0.21 per share, for the three months ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/0000950170-24-013568-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}